CJC-1295 / Ipamorelin Blend
CJC-1295
IpamorelinBlend components — PubChem
Research Hub — Aggregated Studies
MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.
This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.
MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.
Purchaser Restrictions
- Purchaser must be a qualified researcher at an accredited institution or licensed research facility
- This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
- Not intended for human or animal consumption, diagnostic use, or therapeutic application
- Institutional affiliation and research purpose will be verified prior to order fulfillment
Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).
| Risk Tier | YELLOW |
| Category | Growth Hormone Axis |
| Subcategory | Synergistic GH Secretagogue Combination |
| Pharmacological Class | Dual-Peptide Combination |
| Subclass | GHRH Analog + Ghrelin Receptor Agonist (GHS) Combination |
| Molecular Type | Blend of two synthetic peptides — CJC-1295 without DAC (modified 30-AA GHRH analog) + Ipamorelin (pentapeptide GH secretagogue) |
| Origin | Both synthetic; targets two independent but synergistic GH release pathways |
| Regulatory Status | Research Use Only. Neither component FDA-approved for therapeutic use. |
| Route of Administration | Subcutaneous injection |
| Reconstitution | Lyophilized powder; reconstitute with bacteriostatic water |
| Storage | Refrigerate (2-8°C) |
Description
The CJC-1295/Ipamorelin blend is a pre-formulated combination of two complementary growth hormone secretagogues that act through independent receptor systems to produce a synergistic GH release response significantly greater than either peptide alone. CJC-1295 (without DAC, Modified GRF 1-29) activates the GHRH receptor on pituitary somatotrophs via the cAMP/PKA pathway, while Ipamorelin activates the growth hormone secretagogue receptor (GHS-R1a, also known as the ghrelin receptor) via a Gq/PLC/IP3/Ca2+ signaling cascade. These two pathways converge intracellularly within the somatotroph cell, producing an additive-to-synergistic amplification of GH exocytosis.
The physiological rationale for this combination mirrors the body's own dual-signal system: endogenous GHRH from the hypothalamus provides the primary "go" signal for GH release, while endogenous ghrelin from the stomach provides a concurrent amplifying signal. The combination recapitulates this dual-receptor activation pharmacologically. Published studies have demonstrated that co-administration of a GHRH analog and a ghrelin mimetic can produce GH release amplitudes 2-3 times greater than either agent alone. Additionally, ipamorelin's selectivity (it does not stimulate cortisol, prolactin, or appetite — unlike other ghrelin mimetics such as GHRP-6 or hexarelin) makes it an ideal pairing with CJC-1295, as the combination produces robust GH release without the unwanted neuroendocrine side effects associated with less selective GH secretagogues.
Clinical Context
The CJC-1295/Ipamorelin blend has become the most widely used GH secretagogue combination in the peptide research and clinical space. Its popularity stems from the synergistic GH release, the clean side-effect profile (no cortisol/prolactin/appetite stimulation), and the convenience of a pre-blended formulation. The 5mg/5mg blend at $40.15 represents excellent value compared to purchasing each component separately. This combination is often considered the "gold standard" starting point for GH axis optimization protocols.
- The combination produces more robust GH release than either component alone — start with conservative dosing
- Ipamorelin's selectivity means no cortisol, prolactin, or appetite stimulation — a significant advantage over GHRP-6 or hexarelin combinations
- Administer on an empty stomach; food (especially fats and carbohydrates) blunts the GH response
- Evening/bedtime dosing preferred to augment natural nocturnal GH surge
- Both components require a functional pituitary gland
- IGF-1 monitoring recommended to ensure levels remain within appropriate ranges
- Pre-blended formulation eliminates the need for separate reconstitution and injection
Published Research
Published Research & Clinical Data
Peer-reviewed studies and clinical trial data related to CJC-1295 / Ipamorelin Blend
All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.
Research citations are being compiled for this compound.
Check back soon — our team is curating peer-reviewed sources.